JP2021516241A5 - - Google Patents

Info

Publication number
JP2021516241A5
JP2021516241A5 JP2020546984A JP2020546984A JP2021516241A5 JP 2021516241 A5 JP2021516241 A5 JP 2021516241A5 JP 2020546984 A JP2020546984 A JP 2020546984A JP 2020546984 A JP2020546984 A JP 2020546984A JP 2021516241 A5 JP2021516241 A5 JP 2021516241A5
Authority
JP
Japan
Prior art keywords
component
kit according
administered
treatment
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020546984A
Other languages
English (en)
Japanese (ja)
Other versions
JP7384812B2 (ja
JP2021516241A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020576 external-priority patent/WO2019173230A1/en
Publication of JP2021516241A publication Critical patent/JP2021516241A/ja
Publication of JP2021516241A5 publication Critical patent/JP2021516241A5/ja
Priority to JP2023191863A priority Critical patent/JP7662746B2/ja
Application granted granted Critical
Publication of JP7384812B2 publication Critical patent/JP7384812B2/ja
Priority to JP2025061262A priority patent/JP2025096361A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020546984A 2018-03-05 2019-03-04 アリピプラゾール投与戦略 Active JP7384812B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023191863A JP7662746B2 (ja) 2018-03-05 2023-11-09 アリピプラゾール投与戦略
JP2025061262A JP2025096361A (ja) 2018-03-05 2025-04-02 アリピプラゾール投与戦略

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862638587P 2018-03-05 2018-03-05
US62/638,587 2018-03-05
PCT/US2019/020576 WO2019173230A1 (en) 2018-03-05 2019-03-04 Aripiprazole dosing strategy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191863A Division JP7662746B2 (ja) 2018-03-05 2023-11-09 アリピプラゾール投与戦略

Publications (3)

Publication Number Publication Date
JP2021516241A JP2021516241A (ja) 2021-07-01
JP2021516241A5 true JP2021516241A5 (cg-RX-API-DMAC7.html) 2022-03-16
JP7384812B2 JP7384812B2 (ja) 2023-11-21

Family

ID=65818625

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020546984A Active JP7384812B2 (ja) 2018-03-05 2019-03-04 アリピプラゾール投与戦略
JP2023191863A Active JP7662746B2 (ja) 2018-03-05 2023-11-09 アリピプラゾール投与戦略
JP2025061262A Pending JP2025096361A (ja) 2018-03-05 2025-04-02 アリピプラゾール投与戦略

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023191863A Active JP7662746B2 (ja) 2018-03-05 2023-11-09 アリピプラゾール投与戦略
JP2025061262A Pending JP2025096361A (ja) 2018-03-05 2025-04-02 アリピプラゾール投与戦略

Country Status (7)

Country Link
US (3) US11273158B2 (cg-RX-API-DMAC7.html)
EP (1) EP3761983A1 (cg-RX-API-DMAC7.html)
JP (3) JP7384812B2 (cg-RX-API-DMAC7.html)
CN (1) CN112423754A (cg-RX-API-DMAC7.html)
AU (1) AU2019230014B2 (cg-RX-API-DMAC7.html)
CA (1) CA3092335A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019173230A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
AU2019230014B2 (en) * 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US20230129919A1 (en) * 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
WO2022146462A1 (en) * 2020-12-31 2022-07-07 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole

Family Cites Families (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1160099A (en) 1911-10-04 1915-11-09 Mark Cangen Heel-breast-scouring machine.
US2418499A (en) 1944-06-20 1947-04-08 Du Pont 2-alkoxymethylmercapto-thiazoles and thiazolines and a process for preparing the same
DE1070760B (de) 1955-11-19 1959-12-10 Badische Anilin- S- Soda-Fabrik Aktiengesellschaft, Ludwigshafen / Rhein Verfahren zur Herstellung von Azofarbstoffen
GB849541A (en) 1956-02-23 1960-09-28 Rohm & Haas Preparation of unsaturated cyclic urea derivatives
DE1273533B (de) 1962-09-08 1968-07-25 Hoechst Ag Verfahren zur Herstellung von N-(ª‡-Alkoxy-alkyl)-carbonsaeureamiden
NL128370C (cg-RX-API-DMAC7.html) 1964-08-28
US3523121A (en) 1967-03-09 1970-08-04 Rohm & Haas Certain 2-carbamoyl-3-isothiazolenes
US3573308A (en) 1969-04-03 1971-03-30 Hoffmann La Roche 3-lower alkoxy methyl-3,4-dihydro-4-hydroxy-4-aryl quinazolin-2(1h) ones and related compounds
US3957808A (en) 1969-09-03 1976-05-18 Rohm And Haas Company 3-alkoxyisothiazoles
US3798219A (en) 1971-10-18 1974-03-19 Warner Lambert Co 3-(methylsulfinyl)cinnolinones and their derivatives
US3998815A (en) 1974-06-24 1976-12-21 Interx Research Corporation 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
US4727151A (en) 1974-06-24 1988-02-23 Interx Research Corporation Labile quaternary ammonium salts as prodrugs
US4204065A (en) 1975-09-22 1980-05-20 Interx Research Corporation Soft quaternary surface active agents and method of using same
JPS5331676A (en) 1976-09-06 1978-03-25 Mitsui Toatsu Chem Inc Uracil derivatives and their preparation
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0005828B1 (de) 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
US4297129A (en) 1979-04-27 1981-10-27 Sumitomo Chemical Company, Limited 3,5-Dioxo-1,2,4-triazines
JPS568318A (en) 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
DE3149010A1 (de) 1981-12-10 1983-07-07 A. Nattermann & Cie GmbH, 5000 Köln (+)-2-(1-(2,6-dichlorphenoxy)-ethyl)-1,3- diazacyclopent-2-en, dessen herstellung und seine verwendung in pharamazeutischen praeparaten
US4428935A (en) 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
US4448906A (en) 1982-06-16 1984-05-15 Nuodex Inc. Surface-coating compositions
IT1212743B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Sali quaternari di derivati di benzo[ 1,4 ]diazepinonici,pirido [1,4]benzodiazepinonici,prido [1,5]benzodiazepinonici e loro atti vita' farmacologica
JPS602331A (ja) 1983-06-20 1985-01-08 Yoshino Kogyosho Co Ltd 飽和ポリエステル樹脂製壜の成形方法
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
DK302883D0 (da) 1983-06-30 1983-06-30 Hans Bundgaard Allopurinol prodrugs
US4500708A (en) 1984-04-23 1985-02-19 G. D. Serle & Co. Benzothiazine derivatives
DE3544134A1 (de) 1984-12-15 1986-06-19 Mitsubishi Chemical Industries Ltd., Tokio/Tokyo Verfahren zur herstellung von n-((alpha)-alkoxyethyl) pyrrolidon
JPS61171467A (ja) 1985-01-23 1986-08-02 Mitsubishi Chem Ind Ltd N−(α−アルコキシエチル)ピロリドンの製造方法
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
GB8513754D0 (en) 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
FR2587029B1 (fr) 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
JPS63284165A (ja) 1987-05-14 1988-11-21 Sankyo Co Ltd 5−フルオロウラシル誘導体
US4925860A (en) 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
GB8809978D0 (en) 1988-04-27 1988-06-02 Ici Plc Anti-tumour agents
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DK24089D0 (da) 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
GB9007569D0 (en) 1990-04-04 1990-05-30 Nycomed As Carbo-nucleoside derivatives
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
DK238190D0 (da) 1990-10-03 1990-10-03 Lundbeck & Co As H Depotderivater
US5206386A (en) 1991-03-20 1993-04-27 Isp Investments Inc. Controlled release N-substituted pyrrolidone esters and process for the use thereof
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
TW226016B (cg-RX-API-DMAC7.html) 1991-12-30 1994-07-01 Sterling Winthrop Inc
JPH05194517A (ja) 1992-01-16 1993-08-03 Tanabe Seiyaku Co Ltd 6−メルカプトプリン誘導体及びその製法
US5462934A (en) 1992-03-09 1995-10-31 Takeda Chemical Industries Condensed heterocyclic ketone derivatives and their use
AU4534593A (en) 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
ATE185564T1 (de) 1992-08-31 1999-10-15 Sankyo Co Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung
WO1994020508A1 (en) 1993-03-08 1994-09-15 Eisai Co., Ltd. Phosphonic acid derivatives
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE4439493A1 (de) 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
HUP9800631A3 (en) 1995-02-28 1998-12-28 Lundbeck & Co As H 4-aminotetrahydrobenzisoxazole or -isothiazole derivatives, pharmaceutical compositions containing them and their use for the preparation of pharmaceutical compositions
JP3571795B2 (ja) 1995-04-18 2004-09-29 株式会社日本触媒 N−(1−アルキルオキシアルキル)カルバメート類の気相分子内脱アルコール反応用触媒およびn−ビニルカルバメート類の製造方法
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
PL187926B1 (pl) 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
PT889889E (pt) 1996-03-29 2007-01-31 Duphar Int Res Composto de piperazina e piperidina
NZ332115A (en) 1996-04-30 2000-05-26 Warner Lambert Co Improved process for the synthesis of diesters of phosphoric acid 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester
DE19619819A1 (de) 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltenden Arzneimittel
RU2186562C2 (ru) 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
SK146199A3 (en) 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
AU752552C (en) 1997-09-30 2003-09-11 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
PT1114028E (pt) 1998-08-26 2007-02-28 Aventis Pharma Ltd Aza-biciclos moduladores da inibição da adesão celular
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2004501067A (ja) 2000-01-28 2004-01-15 ローム アンド ハース カンパニー 高められた特性をもつ医薬
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6656505B2 (en) 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
MXPA03005870A (es) 2001-02-14 2005-02-14 Warner Lambert Co Inhibirores de benzotiadiazina de metaloproteinasas de la matriz.
US20060293217A1 (en) 2001-03-19 2006-12-28 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
JP2005511477A (ja) 2001-03-19 2005-04-28 プラエシス ファーマシューティカルズ インコーポレーテッド 持続放出のための医薬調合物
EP1414798A2 (en) 2001-04-03 2004-05-06 Aryx Therapeutics Ultrashort-acting opioids for transdermal application
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
WO2002100861A1 (en) 2001-06-13 2002-12-19 Akzo Nobel N.V. 1-(3-phenyloxypropyl)piperidine derivatives
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ATE416168T1 (de) 2002-02-15 2008-12-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
GEP20074230B (en) 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
AU2003236365A1 (en) 2002-04-05 2003-10-20 Sankyo Company, Limited Medicinal composition comprising acat inhibitor and insuline resistance improving agent
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
NZ537995A (en) 2002-08-20 2007-11-30 Bristol Myers Squibb Co Inclusion complex of aripiprazole in a substituted b-cyclodextrin
EA200500342A1 (ru) 2002-09-17 2005-08-25 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Гетероциклические замещённые пиперазины для лечения шизофрении
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CA2497765A1 (en) 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Co., Ltd. 8-hydroxy substituted adenine compounds and uses thereof
PL376721A1 (pl) 2002-10-24 2006-01-09 Pfizer Products Inc. Pochodne acylowe 5-(2-(4-(1,2-benzoizotiazol-3-ilo)-1-piperazynylo) etylo)-6-chloro-1,3-dihydro-2H-indol-2-onu o działaniu neuroleptycznym
NZ540769A (en) 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
WO2004056305A2 (en) 2002-12-18 2004-07-08 Algorx Administration of capsaicinoids
DE10303669A1 (de) 2003-01-28 2004-07-29 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Tetraalkylammoniumsalze vom Kohlensäureestertyp, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ZA200508306B (en) 2003-05-23 2007-03-28 Otsuka Pharma Co Ltd Carbostyril derivatives and mood stabilizers for treating mood disorders
PL1651265T3 (pl) 2003-07-24 2008-10-31 Merial Ltd Formulacje szczepionek zawierających emulsję olej w wodzie
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CN100559182C (zh) 2003-08-29 2009-11-11 株式会社东芝 显色试剂、浓度测定试剂盒、浓度测定方法和在该方法中使用的传感器芯片
BRPI0415531B8 (pt) 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
MXPA06007654A (es) 2003-12-31 2006-09-04 Warner Lambert Co Derivados de piperidina n-sustituidos.
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
CA2556160A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US7169803B2 (en) 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
JP4840594B2 (ja) 2004-03-23 2011-12-21 日産化学工業株式会社 抗不整脈薬としての3環性ベンゾピラン化合物
US7119214B2 (en) 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
GB2413795A (en) 2004-05-05 2005-11-09 Cipla Ltd Process for the preparation of rosiglitazone
WO2005120577A2 (en) 2004-06-09 2005-12-22 Ramot At Tel Aviv University Ltd. Derivatives of chemotherapeutic agents with a formaldehyde releasing moeity
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
WO2006037090A2 (en) 2004-09-28 2006-04-06 Purdue Research Foundation Drug-phosphate conjugates as prodrugs
EP2623095A1 (en) 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US20080233053A1 (en) 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
GB0502573D0 (en) 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
EP1891956B1 (en) 2005-06-13 2012-08-29 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
WO2007035348A2 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007052104A2 (en) 2005-10-31 2007-05-10 Pfizer Products Inc. Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
WO2007059111A2 (en) 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
AU2007207743B2 (en) 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
TW200804359A (en) 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
AU2007223342A1 (en) 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
EP2059245A1 (en) 2006-08-31 2009-05-20 Solvay Pharmaceuticals B.V. Bifeprunox doses for treating schizophrenia
US20090068290A1 (en) 2006-08-31 2009-03-12 Michel Bourin Bifeprunox doses for treating schizophrenia
TW200829244A (en) 2006-09-15 2008-07-16 Astrazeneca Ab Therapeutic combinations 482
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
EP2121029A2 (en) 2006-12-05 2009-11-25 Neurogesx, Inc. Prodrugs and methods of making and using the same
AR064307A1 (es) 2006-12-13 2009-03-25 Gilead Sciences Inc Monofosfatos utiles para el tratamiento de la inflamacion pulmonar y broncoconstriccion, formulaciones aerosolicas que los contienen, y metodo de preparacion.
EP2120909A2 (en) 2006-12-15 2009-11-25 Ordway Research Institute Treatments of therapy-resistant diseases comprising drug combinations
TWI325694B (en) 2006-12-15 2010-06-01 Ind Tech Res Inst All digital delay locked loop
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
HRP20130041T8 (en) 2007-04-04 2013-03-31 Merck Sharp & Dohme Corp. Therapeutic agents
RU2497819C2 (ru) 2007-05-21 2013-11-10 Ривайва Фармасьютикалс, Инк. Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
US20100292316A1 (en) 2007-07-18 2010-11-18 Research Development Foundation Improved therapeutic methods and compositions comprising chroman ring compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW200924746A (en) 2007-09-07 2009-06-16 Xenoport Inc Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
WO2009052467A1 (en) 2007-10-19 2009-04-23 Board Of Regents Of The University Of Texas System Methods of identifying pi-3-kinase inhibitor resistance
WO2009060473A2 (en) 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US20110003823A1 (en) 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
AU2009288200A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
US8017515B2 (en) 2008-12-10 2011-09-13 Stats Chippac, Ltd. Semiconductor device and method of forming compliant polymer layer between UBM and conformal dielectric layer/RDL for stress relief
PL2389372T3 (pl) 2009-01-23 2016-02-29 Rigel Pharmaceuticals Inc Kompozycje i sposoby hamowania szlaku JAK
NZ594071A (en) 2009-01-26 2013-01-25 Egalet Ltd Controlled release formulations comprising morphine sulphate for continuous treatment of pain
US20100286136A1 (en) 2009-05-08 2010-11-11 Simon Jones Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
US8190546B2 (en) 2009-05-15 2012-05-29 At&T Intellectual Property I, L.P. Dependency between sources in truth discovery
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
PE20121048A1 (es) 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AU2010313290A1 (en) 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
US20110166128A1 (en) 2010-01-07 2011-07-07 Alkermes, Inc. Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders
EP2521545B1 (en) 2010-01-07 2019-11-27 Alkermes Pharma Ireland Limited Prodrugs of heteroaromatic compounds
WO2011084851A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Asenapine produrugs
WO2011084850A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Prodrugs for the treatment of schizophrenia and bipolar disease
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
KR101792891B1 (ko) 2010-02-16 2017-11-20 하마마츠 포토닉스 가부시키가이샤 가스 농도 산출 장치 및 가스 농도 계측 모듈
JP5857040B2 (ja) 2010-05-04 2016-02-10 アルカーメス ファーマ アイルランド リミテッド 酸化ラクタム化合物の合成方法
CN102260290A (zh) 2010-05-25 2011-11-30 苏州波锐生物医药科技有限公司 喹喏啉酮类化合物及其在制备精神病药物中的用途
AU2011268073B2 (en) 2010-06-18 2015-07-16 Takeda Pharmaceutical Company Limited D2 antagonists, methods of synthesis and methods of use
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP6013364B2 (ja) 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルapiローディングプロドラッグ
ES2972387T3 (es) * 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US10016415B2 (en) * 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
SMT202100212T1 (it) 2014-08-25 2021-07-12 Alkermes Pharma Ireland Ltd Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia
AU2019230014B2 (en) * 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Similar Documents

Publication Publication Date Title
JP2018184417A5 (cg-RX-API-DMAC7.html)
JP2023002544A5 (cg-RX-API-DMAC7.html)
JP6099609B2 (ja) 肺炎症を低減するためのレボフロキサシンの吸入
JP2018514534A5 (cg-RX-API-DMAC7.html)
JP2020517696A5 (cg-RX-API-DMAC7.html)
JP2014502968A5 (cg-RX-API-DMAC7.html)
JP2015529225A5 (cg-RX-API-DMAC7.html)
JP7175897B2 (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
IL314873A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
JP2016518387A5 (cg-RX-API-DMAC7.html)
WO2002094273A3 (en) Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
JP2019516684A5 (cg-RX-API-DMAC7.html)
JP2019517587A5 (cg-RX-API-DMAC7.html)
JP2012502047A5 (cg-RX-API-DMAC7.html)
JP2006513184A5 (cg-RX-API-DMAC7.html)
JP2016534996A5 (cg-RX-API-DMAC7.html)
JP2022549621A5 (cg-RX-API-DMAC7.html)
JP2021526138A5 (cg-RX-API-DMAC7.html)
JP2018502168A5 (cg-RX-API-DMAC7.html)
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
JP2018529766A5 (cg-RX-API-DMAC7.html)
JP2022546456A5 (cg-RX-API-DMAC7.html)
JP2023553253A5 (cg-RX-API-DMAC7.html)
JP2019532112A5 (ja) 結節性痒疹を治療するための抗掻痒剤